Trial Profile

A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KUR-113 (Primary)
Indications Fracture
Focus First in man; Therapeutic Use
Sponsors Kuros Biosurgery

Most Recent Events

20 Jan 2022 According to Kuros Biosciences media release, data of this study published in peer-reviewed Journal of Bone and Joint Surgery
20 Jan 2022 Results published in the Kuros Biosciences Media Release
20 Jan 2016 Primary endpoint 'Proportion of patients healed 6 months after the surgery' has been met, according to a Kuros Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com